Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Men with a BRCA1 or BRCA2 mutation have an increased lifetime risk for prostate cancer. Prostate cancers in these men may be more likely to:
Prostate cancer screening includes the following:
Annual prostate cancer screening is recommended for men with BRCA2 mutation, and should be considered for men with BRCA1 mutations beginning at age 40.
Men with mutations in BRCA1, BRCA2 or other, such as ATM, may qualify for prostate cancer screening clinical trials. Visit our research study page for links to clinical trials for early detection of pancreatic cancer.